Apellis SYFOVRE Sales Fall 4% on Rising Volume, Exposing a CVR Worth Zero

NEW YORK, April 1 -

SYFOVRE injection volumes rose 17% in 2025. Revenue fell 4% to $587mn. That gap tells you what Biogen actually bought. and what the CVR is actually worth.

What the Street Believes

Wall Street has largely made peace with $41/share. The logic runs like this: Biogen's sprawling commercial infrastructure fixes what ails SYFOVRE's underwhelming revenue trajectory, and the contingent value right. up to $4/share extra if sales hit milestones. is a cherry on top. It's a clean merger-arb trade with a small lottery ticket stapled to the back.

The problem is that the lottery ticket is drawn from a hat with no winning numbers in it. At $40.23, the stock prices in near-certainty the base deal closes. The CVR is treated as a free option. But two facts the consensus is sleepwalking past. a widening gap between gross and net revenue, and two competitors arriving before the CVR measurement window closes. suggest the option's strike price sits in a zip code SYFOVRE will never visit. Merger arbs positioning for anything above $41 are paying for a fiction.

What the Data Shows

Here's the number that should be on every APLS holder's whiteboard: more patients got SYFOVRE injections in 2025 than in 2024, and Apellis collected less money. Not less money per injection. less money, full stop. That's like a restaurant serving 17% more tables and reporting lower revenue. It doesn't mean the food is bad. It means someone else is picking up the check, and that someone is a payer ecosystem that's squeezing net realizations harder with every passing quarter. For long holders banking on the CVR, this is the sound of the exit door closing.

"Apellis shareholders are eligible to receive up to an additional $4 per share via a non-transferable CVR if SYFOVRE achieves $1.5 billion in annual global net sales in any calendar year between 2027 and 2030, with an additional tier at $2 billion. milestones JPMorgan's model does not assume will be reached."

Run the arithmetic and it borders on absurd. Reaching $1.5bn from $587mn requires a 155% jump in net sales. That demands either tripling injection volume at stable pricing. a fantasy when pricing is actively deteriorating. or reversing copay assistance erosion in a retinal market where Iveric Bio's Izervay already competes and Regeneron/Alnylam's C5 combination is expected by late 2027. You'd need a miracle in a market that's about to get more crowded, not less. Every new entrant gives payers more leverage to widen the gross-to-net spread further.

Wait. it gets worse. The CVR's non-transferable structure is the quiet tell that even the deal architects didn't believe in it. In most biotech acquisitions, CVRs trade separately on OTC markets. Arbs strip them from the base consideration, and the secondary market assigns a probability-weighted value. usually pennies on the dollar, but real pennies with real price discovery. Apellis holders get none of that. The CVR sits locked inside the arb position like a safe deposit box nobody can open until 2027 at the earliest. There's no independent market to test whether it's worth $0.50 or $0.00. That's not an oversight. It's a structure designed by people who did the math. Any investor treating this CVR as incremental value is valuing something that has no mechanism to prove them right until it's too late to act on it.

Why This Changes the Calculus

Strip away the CVR mirage and the acquisition price is $41 flat. Not $43. Not $45. JPMorgan's own model. the bank advising on the deal. assumes neither CVR milestone is met. When your own banker doesn't believe in the upside case, that's not conservatism. That's the base case wearing a name tag. Street models ranging from $41 to $45 in total consideration are really a distribution between "$41 and wishful thinking." The data supports the low end, period.

At $41/share, Biogen is paying roughly $5.6bn for a business burning $15mn in TTM free cash flow. Think about that ratio for a moment. The entire growth case now pivots to Empaveli's expansion into C3 glomerulopathy and other nephrology indications. a pipeline franchise being asked to carry a flagship product whose economics are eroding in real time. It's like buying a house because the garden has potential, while the roof leaks progressively worse each quarter. The garden might bloom eventually, but the carrying cost matters enormously.

The number to watch: Q1 2026 SYFOVRE net revenue per injection. If the gross-to-net spread widens further, even $41 starts to look generous. Each quarter of continued pricing erosion makes the Empaveli nephrology bet more binary. either it works spectacularly, or Biogen overpaid for a declining asset with a promising sidebar. There is no middle-ground scenario where SYFOVRE stabilizes gently while Empaveli ramps slowly.

The Counterargument

Fair is fair: Biogen's infrastructure is genuinely formidable. A larger salesforce, stronger payer negotiating leverage, and international expansion pathways could theoretically stabilize the gross-to-net trend. Biogen has wrestled with specialty pharmacy economics before. Tecfidera's pricing lifecycle wasn't pretty, but the company knows the mechanics. Empaveli's nephrology pipeline, particularly in C3 glomerulopathy, targets a genuine unmet need with limited competition, and early data has been encouraging enough to justify real pipeline value.

The earnings trend offers a data point worth respecting: Q2 2025 delivered $1.67 EPS versus $0.94 consensus, a 77.5% beat. That quarter proved operational leverage exists when volume converts to revenue. when net realizations hold, the model works. Bulls will argue that's the template for what Biogen's commercial engine can replicate at scale.

But one strong quarter doesn't erase structural pricing decay any more than one sunny day ends a drought. The 17%-volume-up, 4%-revenue-down split isn't a timing issue or a reimbursement lag that smooths out. It reflects payer dynamics baked into SYFOVRE's market architecture. dynamics that a bigger salesforce writing more prescriptions actually makes worse, not better, because higher utilization gives payers more incentive to tighten formulary terms. Biogen would need to overhaul SYFOVRE's entire copay architecture. mid-launch, mid-competition, mid-acquisition integration. to reverse the trend. That's three simultaneous knife-juggles, and the knives are getting sharper.

Verdict

The real acquisition price is not the headline $45. When Biogen announced the $5.6 billion deal, the CVR looked like real upside. a credible bridge between a conservative base price and SYFOVRE's theoretical peak-sales potential. The gross-to-net data demolished that bridge. At $41, you own a cash-flow-negative ophthalmology franchise facing two new competitors with every incentive to undercut on pricing, plus an early-stage nephrology pipeline that needs to work perfectly to justify what Biogen paid. The CVR is a rounding error dressed as optionality. the biotech equivalent of a coupon for a store that's already closing. Position accordingly.

Frequently Asked Questions

What is the APLS–Biogen CVR worth?

The CVR pays up to $4/share if SYFOVRE hits $1.5bn–$2.0bn in annual net sales between 2027 and 2030. With 2025 revenue at $587mn and the gross-to-net spread widening, reaching the lower threshold requires a 155% increase in net sales. a hurdle JPMorgan's own advisory model does not assume will be met. The non-transferable structure means no secondary market exists to assign an independent value. Based on current trajectory and incoming competition, the CVR's expected value rounds to zero.

Why did SYFOVRE revenue fall while injection volume rose?

Net revenue per injection declined enough to more than offset 17% volume growth, pushing total 2025 revenue down 4% to $587mn. The culprit is a widening gross-to-net spread driven by copay assistance programs and payer reimbursement pressure. structural forces that intensify as utilization rises and new competitors like Izervay give formulary committees more negotiating leverage.

What competitors threaten SYFOVRE's market share?

Iveric Bio's Izervay is already on the market competing for geographic atrophy patients. Regeneron and Alnylam's C5 combination therapy is expected by late 2027, arriving squarely within the CVR measurement window and likely adding further pricing pressure in the retinal space.

Basis Report is not a registered investment adviser and does not provide personalized financial advice. All content is for educational and informational purposes only. Always conduct your own analysis and consider consulting a qualified financial advisor before making investment decisions.